Shares of Akebia Therapeutics Inc (NASDAQ:AKBA) rose 5.2% during trading on Monday . The company traded as high as $4.32 and last traded at $4.28, approximately 575,500 shares traded hands during trading. A decline of 47% from the average daily volume of 1,079,053 shares. The stock had previously closed at $4.07.

A number of analysts have recently weighed in on AKBA shares. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Akebia Therapeutics in a research note on Monday. Zacks Investment Research upgraded shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, July 12th. ValuEngine raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Mizuho set a $16.00 target price on Akebia Therapeutics and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, BidaskClub downgraded Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $12.45.

The business has a fifty day moving average of $4.21 and a 200-day moving average of $5.54. The stock has a market capitalization of $508.74 million, a price-to-earnings ratio of -2.16 and a beta of 1.43. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.70 and a quick ratio of 1.05.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.05. Akebia Therapeutics had a negative net margin of 75.64% and a negative return on equity of 36.92%. The firm had revenue of $100.80 million for the quarter, compared to analysts’ expectations of $88.35 million. As a group, research analysts anticipate that Akebia Therapeutics Inc will post -1.41 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in AKBA. BlackRock Inc. raised its holdings in shares of Akebia Therapeutics by 20.6% in the 2nd quarter. BlackRock Inc. now owns 10,227,690 shares of the biopharmaceutical company’s stock worth $49,501,000 after purchasing an additional 1,745,307 shares in the last quarter. Nuveen Asset Management LLC acquired a new stake in Akebia Therapeutics during the second quarter valued at approximately $7,885,000. Point72 Asset Management L.P. lifted its stake in Akebia Therapeutics by 1,523.4% during the second quarter. Point72 Asset Management L.P. now owns 1,623,400 shares of the biopharmaceutical company’s stock valued at $7,857,000 after purchasing an additional 1,523,400 shares during the last quarter. Clearbridge Investments LLC boosted its holdings in Akebia Therapeutics by 3.4% during the first quarter. Clearbridge Investments LLC now owns 1,257,336 shares of the biopharmaceutical company’s stock worth $10,298,000 after buying an additional 41,450 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Akebia Therapeutics by 2.8% during the second quarter. Northern Trust Corp now owns 1,152,582 shares of the biopharmaceutical company’s stock worth $5,578,000 after buying an additional 31,036 shares in the last quarter. 71.88% of the stock is currently owned by institutional investors.

Akebia Therapeutics Company Profile (NASDAQ:AKBA)

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.

Read More: Conference Calls

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.